Clinical trials: Anthracyclines
Breast Cancer
NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?
The purpose of this study is to evaluate the usual and the reverse sequence of an anthracycline followed by a taxane in locally advanced breast cancer.
- Trial name
- NeoSAMBA (NCT01270373)
- Testing
- FAC x 3 followed by Docetaxel x 3, Docetaxel x 3 followed by FAC x 3
- Where
- Brazil
- Volunteers
- 112 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Participants Undergoing Anthracycline Chemotherapy
Remote Ischemic Conditioning in Oncology
This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements…
- Trial name
- RICO (NCT04805346)
- Testing
- autoRIC®
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cardiac Complications
Magnetic Resonance Imaging:A Window to Anthracycline Toxicity
The study is being conducted to see which cardiac tests that monitor how the heart functions during and after treatment with anthracyclines are most effective.
- Trial name
- NCT03211520
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Connecticut Children's Medical Center
Breast Cancer
Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)
Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom Baker Cancer Centre (TBCC) and included into the study, if they are going to receive chemotherapy with anthracyclines and / or Trastuzumab…
- Trial name
- Cardiotox (NCT00679874)
- Testing
- Cardio-vascular MRI
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University of Calgary
Sarcoma
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064220
- Testing
- soblidotin
- Where
- 6 sites in United States, Puerto Rico
- Sponsor
- Daiichi Sankyo
Childhood Cancer
Cardiac 3D MRI in Pediatric Cancer Patients
This is a non-randomized prospective pilot study in a single academic center with historic controls. This study will compare Cardiac Magnetic Resonance Images (MRI) of patients who have undergone childhood cancer treatment that…
- Trial name
- NCT02130934
- Testing
- Cardiac 3D MRI
- Where
- 2 sites in United States
- Sponsor
- Majd Makhoul
Wilms Tumor, Neuroblastoma
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .
- Conditions
- Wilms Tumor, Neuroblastoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia
- Trial name
- Doxo (NCT01095926)
- Testing
- doxorubicin
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- University Hospital Muenster
Heart Injuries, Anthracycline
Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients
The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Anthracycline chemotherapy.
- Trial name
- NCT06898320
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- IRCCS Burlo Garofolo
Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity
Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline
In recent decades, the survival rate of children with cancer has increased significantly thanks to personalized treatments and the adoption of international therapeutic protocols.
- Conditions
- Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity, Childhood Cancer Survivors
- Trial name
- CARDIO-PED (NCT07253077)
- Testing
- Biomarker detection
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Osteosarcoma, Ewing's Sarcoma Family of Tumors
Markers of Anthracycline-Related Cardiac Muscle Injury
Anthracycline antibiotics are included in the chemotherapy regimens of approximately 82% of patients with bone cancer and 44% of those with soft tissue sarcoma diagnosed in childhood or adolescence.
- Conditions
- Osteosarcoma, Ewing's Sarcoma Family of Tumors, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcomas
- Trial name
- NCT01112800
- Sponsor
- St. Jude Children's Research Hospital
Breast Cancer
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003032
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 25 sites in Canada
- Volunteers
- 224 people
- Sponsor
- NCIC Clinical Trials Group
Anthracycline-induced Cardiotoxicity
Preventing Cardiac Sequelae in Pediatric Cancer Survivors
Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death.
- Trial name
- PCS2 (NCT01805778)
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,128 people
- Sponsor
- The Hospital for Sick Children
Testicular Neoplasms
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
St Bartholomew's hospital completed a study using the regimen GAMEC (PEG-filgrastim, actinomycin-D, methotrexate, etoposide, cisplatin).
- Trial name
- GAMEC-II (NCT06309732)
- Testing
- Pegfilgrastim, Dactinomycin, Methotrexate
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Queen Mary University of London
Progression-free Survival, Overall Survival
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Advanced soft tissue sarcoma patients who have previously recieved anthracyclines might still benefit from doxorubicin, ifosfamide and dacarbazine.
- Conditions
- Progression-free Survival, Overall Survival, Toxicity
- Trial name
- PDVPSTS (NCT03342300)
- Testing
- pegylated liposomal doxorubicin, pirarubicin
- Where
- China
- Sponsor
- Peking University People's Hospital
Cardiotoxicity, Osteosarcoma
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular…
- Conditions
- Cardiotoxicity, Osteosarcoma, Myocardial Injury, Chemotherapy Induced Systolic Dysfunction
- Trial name
- NCT04461223
- Testing
- contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- 15-95 (NCT00002784)
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 11 sites in Australia, Switzerland
- Volunteers
- 344 people
- Sponsor
- ETOP IBCSG Partners Foundation
Cardiotoxicity
Effect of Remote Ischaemic Conditioning in Oncology Patients
Cancer survival has improved steadily due to earlier detection and treatment. Despite the established efficacy of anthracycline chemotherapy, its damaging effects on the heart (cardiotoxicity) limits treatment and confers acute…
- Trial name
- ERIC-ONC (NCT02471885)
- Testing
- Remote Ischaemic Conditioning
- Where
- United Kingdom
- Volunteers
- 128 people
- Sponsor
- University College, London
Breast Cancer
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
The goal of this clinical research study is to learn if Tarceva® (erlotinib hydrochloride) can help control triple receptor-negative breast cancer. The safety of this drug will also be studied.
- Trial name
- NCT00739063
- Testing
- Tarceva
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Cardiotoxicity
Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy
Over 50% of the more than 270,000 childhood cancer survivors in the U.S. have been treated with anthracyclines and thus are at risk of developing cardiotoxicity.
- Trial name
- NCT04036032
- Testing
- Exercise program
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Connecticut Children's Medical Center
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples